As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
Amid Novo Nordisk and Pfizer’s whiplash contest for obesity biotech Metsera, Novo’s CEO has, quite literally, told his company's rival to put its money where its mouth is. “Novo Nordisk and Pfizer ...
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company’s up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer’s strategy for clinical ...
Amid the rapidly unfolding saga revolving around Metsera, a judge has denied Pfizer’s request to block Novo Nordisk’s buyout bid for the biotech, Bloomberg reports. Delaware Chancery Judge Morgan Zurn ...
Novo Nordisk’s CEO dared Pfizer to bid more if it wanted obesity drug developer Metsera so badly. So Pfizer did, with a $10 billion bid that edges out what the Danish pharmaceutical giant was willing ...
“What does your husband do?” Undoubtedly the man who asked me thought it was a harmless question. Subscribe to read this story ad-free Get unlimited access to ad-free articles and exclusive content.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results